• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II

June 28, 2017 By Sarah Faulkner

Teva PharmaceuticalTeva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary endpoints.

The small-molecule inhibitor, TV-45070, was licensed by Xenon to Teva in December 2012.

The Phase II trial enrolled 300 patients and randomized them to receive 4% TV-45070, 8% TV-45070 or placebo twice per day. The primary endpoint was the change of average daily pain scores between baseline and 4 weeks following treatment.

The study’s secondary endpoints were the percentage of patients with more than 30% and greater than 50% improvement in pain scores, quality of life measures and adverse events measurements.

“While these results are disappointing for us from a scientific perspective and for patients needing new therapies to treat chronic neuropathic pain, Xenon remains focused on advancing its pipeline of neurology-related development candidates, with multiple programs anticipated to enter clinical development in 2017,” Xenon president & CEO Simon Pimstone said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Teva Pharmaceuticals, xenonpharmaceuticals

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS